Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
PaperCitations, authors & open-access status
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 550 citations, 2022 year and hybrid oa status.
550
Citations
2022
Year
hybrid
OA Status